Therapy
Health
Cancer Prevention

Inovio

$3.20
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

-$0.10 (-2.99%) Today
-$0.05 (-1.54%) After Hours

Why Robinhood?

You can buy or sell Inovio and other stocks, options, ETFs, and crypto commission-free!

About

Inovio Pharmaceuticals, Inc. Common Stock, also called Inovio, is a late-stage biotechnology company, which engages in the discovery, development, and commercialization of DNA-based immunotherapies and vaccines. Read More Its drug candidates include SynCon immunotherapies which helps break the immune system's tolerance of cancerous cells; and CELLECTRA delivery system which facilitates optimized cellular uptake of the SynCon immunotherapies. The company was founded by David B. Weiner on June 29, 1983 and is headquartered in Plymouth Meeting, PA.

Employees
281
Headquarters
Plymouth Meeting, Pennsylvania
Founded
1983
Market Cap
328.08M
Price-Earnings Ratio
Dividend Yield
0.00
Average Volume
1.02M
High Today
$3.34
Low Today
$3.21
Open Price
$3.32
Volume
349.04K
52 Week High
$6.30
52 Week Low
$3.02

Collections

Therapy
Health
Cancer Prevention
Medical
Pharmaceutical
Technology

News

Yahoo FinanceMay 10

Inovio Q1 Earnings & Revenues Fall Short of Estimates

Inovio Pharmaceuticals, Inc. INO incurred a loss of 30 cents per share for the first quarter of 2019, wider than the Zacks Consensus Estimate of a loss of 29 cents but narrower than the year-ago loss of 36 cents. Inovio generated revenues of $2.8 million in the reported quarter, missing the Zacks Consensus Estimate of $4.4 million. Revenues soared 86.6% from the year-ago quarter’s figure of $1.5 million owing to the milestone payment received from AstraZeneca AZN in the quarter under a collaboration agreem...

349
Yahoo FinanceMay 10

Edited Transcript of INO earnings conference call or presentation 9-May-19 8:30pm GMT

35
Yahoo FinanceMay 10

What You'll Want to Know About Inovio Pharmaceuticals' Q1 Earnings Update

The numbers didn't look very good for Inovio Pharmaceuticals Inc. (NASDAQ: INO) when it announced its fourth-quarter results in March. Revenue fell by 28% year over year while its net loss worsened. But that's par for the course for a clinical-stage biotech. The company announced its first-quarter results after the market closed on Thursday. Here are the highlights from Inovio's Q1 update. Two people in lab coats taking notes and holding test tubes. More Image source: Getty Images. By the numbers Inovi...

218

Earnings

-$0.40
-$0.29
-$0.19
-$0.08
Q3 2017
Q4 2017
Q1 2018
Q2 2018
Q3 2018
Q4 2018
Q1 2019
Estimated
-$0.26 per share
Actual
-$0.30 per share

Popular Stocks

All investments involve risk and the past performance of a security, or financial product does not guarantee future results or returns. Securities offered through Robinhood Financial LLC, member FINRA/SIPC. To learn more about the information provided on this page, please see our Web Disclosures.